

**Table SI. Study flow chart**

Time	-4 weeks -0 day <sup>a</sup>	Day 0 <sup>a</sup>	3 months after V1 <sup>b</sup>	3 months after V2 <sup>b</sup>	6 months after V3 <sup>b</sup>	6 months after V4 <sup>b</sup>	6 months after V5 <sup>b</sup>
Visit	Screening	1	2	3	4	5	6
Study treatment intervention group: DL-PDT		x	x	x	x	x	
Study treatment control group: cryosurgery		x	x <sup>c</sup>	x <sup>c</sup>	x <sup>c</sup>	x <sup>c</sup>	
Documentation of facial AKs		x	x	x	x	x	x
Randomization	x						
Obtaining informed consent	x						
Check of inclusion and exclusion criteria	x	x	x	x	x	x	x
Medical history	x						
Photodocumentation		x	x	x	x	x	x
Assessment of photoageing parameters		x	x	x	x	x	x
Documentation of newly developed malignant skin tumours in the face		x	x	x	x	x	x
Documentation of AEs and SAEs		x	x	x	x	x	x
Pain score (VAS) during treatment		x	x	x	x	x	
DLQI	x						x
Patient satisfaction with cosmetic results			x	x	x	x	x
Investigator satisfaction with cosmetic results			x	x	x	x	x
Local reactions		x	x	x	x	x	
Pregnancy test (if applicable)	x	x	x	x	x	x	

<sup>a</sup>Screening visit (V) and V1 may take place on the same day. <sup>b</sup>± 4 weeks. <sup>c</sup>Cryosurgery only in the case of not-cleared or newly developed actinic keratoses (AKs). x: done ; DL-PDT: daylight photodynamic therapy; AE: adverse events; SAE: serious adverse events; VAS: visual analogue scale; DLQI: Dermatology Life Quality Index.